COMMUNIQUÉS West-GlobeNewswire

Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering
05/02/2026
MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address serious unmet [...]
TruFull CBD Gummies: Product Disclosure Information Updated as CBD Supplement Research Grows in 2026
05/02/2026
Examining hemp-derived CBD supplement disclosures, third-party testing verification, THC-free claims, ingredient transparency, refund policies, and what consumers evaluate when researching full-spectrum CBD gummies in [...]
Neura Cognitive Health Supplement: Ingredient Facts, Label Guide, and Consumer Information for 2026
05/02/2026
An informational overview examining ingredient-level research context, Supplement Facts interpretation, and evaluation factors consumers consider when researching cognitive health supplement options New York, NY, Feb. [...]
Max Force Power Male Enhancement Gummies Product Information Updated as Consumer Interest in Male Vitality Supplement Options Grows in 2026
05/02/2026
An informational overview examining male enhancement supplement category trends, publicly available ingredient disclosures, consumer evaluation criteria, and what adults researching male vitality supplement options [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/02/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
05/02/2026
CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing [...]
IRADIMED CORPORATION to Hold Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 10, 2026
04/02/2026
ORLANDO, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 fourth quarter and full year financial results before the market opens on [...]
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
04/02/2026
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026 [...]
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference
04/02/2026
SAN JOSE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2026
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that [...]
STERIS Announces Financial Results for Fiscal 2026 Third Quarter
04/02/2026
Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53 Fiscal 2026 outlook [...]
Monthly information on share capital and company voting rights
04/02/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
04/02/2026
All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027 [...]
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other [...]
The Ensign Group Reports Fiscal Year and Fourth Quarter 2025 Results; Issues 2026 Annual Earnings and Revenue Guidance
04/02/2026
Conference Call and Webcast scheduled for tomorrow, February 5, 2026 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign [...]
Quipt Home Medical Corp. Announces Filing and Mailing of Proxy Statement and Information Circular and Receipt of Interim Order in Connection With Plan of Arrangement
04/02/2026
CINCINNATI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“ Quipt ” or the “ Company ”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is [...]
MEN Balance Pro Consumer Report (2026): Public Product Information and Evaluation Factors (Not a Review)
04/02/2026
An informational overview examining MEN Balance Pro refund policy terms, retailer disclosures, ingredient transparency, and what consumers evaluate when researching men's wellness supplement options in 2026 WILMINGTON, [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/02/2026
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February 1, 2026, the [...]

Pages